Serum antibodies against prostasomal clusterin in prostate cancer patients

References

• Trougakos I. P., Gonos E. S. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002; 34: 1430–48
   PubMed Web of Science ®Google Scholar
• Trougakos I. P., So A., Jansen B., Gleave M. E., Gonos E. S. Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 2004; 64: 1834–42
   PubMed Web of Science ®Google Scholar
• Pucci S., Bonanno E., Pichiorri F., Angeloni C., Spagnoli L. G. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004; 23: 2298–304
   PubMed Web of Science ®Google Scholar
• Gleave M., Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen‐ and chemo‐sensitivity in prostate cancer. World J Urol 2005; 23: 38–46
   PubMed Web of Science ®Google Scholar
• Sensibar J. A., Sutkowski D. M., Raffo A., Buttyan R., Griswold M. D., Sylvester S. R., et al. Prevention of cell death induced by tumour necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein‐2 (clusterin). Cancer Res 1995; 55: 2431–7
   PubMed Web of Science ®Google Scholar
• Sintich S. M., Steinberg J., Kozlowski J. M., Lee C., Pruden S., Sayeed S., et al. Cytotoxic sensitivity to tumour necrosis factor‐alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP‐2 (clusterin). Prostate 1999; 39: 87–93
   PubMedGoogle Scholar
• Caccamo A. E., Scaltriti M., Caporali A., D'Arca D., Scorcioni F., Astancolle S., et al. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochem J 2004; 382: 157–68
   PubMedGoogle Scholar
• Scaltriti M., Santamaria A., Paciucci R., Bettuzzi S. Intracellular clusterin induces G2‐M phase arrest and cell death in PC‐3 prostate cancer cells1. Cancer Res 2004; 64: 6174–82
   PubMed Web of Science ®Google Scholar
• Zellweger T., Chi K., Miyake H., Adomat H., Kiyama S., Skov K., et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002; 8: 3276–44
   PubMed Web of Science ®Google Scholar
• Pins M. R., Fiadjoe J. E., Korley F., Wong M., Rademaker A. W., Jovanovic B., et al. Clusterin as a possible predictor for biochemical recurrence of prostate cancer following radical prostatectomy with intermediate Gleason scores: a preliminary report. Prost Cancer Prost Dis 2004; 7: 243–8
   PubMed Web of Science ®Google Scholar
• Nilsson B. O., Carlsson L., Larsson A., Ronquist G. Autoantibodies to prostasomes as new markers for prostate cancer. Upsala J Med Sci 2001; 106: 43–50
   PubMed Web of Science ®Google Scholar
• Larsson A., Ronquist G., Wulfing C., Eltze E., Bettendorf O., Carlsson L., et al. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 2006; 24: 195–200
   PubMed Web of Science ®Google Scholar
• Ronquist G., Brody I. The prostasome: its secretion and function in man. Biochim Biophys Acta 1985; 822: 203–18
   PubMed Web of Science ®Google Scholar
• Sahlen G., Ahlander A., Frost A., Ronquist G., Norlen B. J., Nilsson B. O. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004; 61: 291–7
   PubMed Web of Science ®Google Scholar
• Carlsson L., Nilsson O., Larsson A., Stridsberg M., Sahlen G., Ronquist G. Characteristics of human prostasomes isolated from three different sources. Prostate 2003; 54: 322–30
   PubMed Web of Science ®Google Scholar
• Ronquist K. G., Carlsson L., Ronquist G., Nilsson S., Larsson A. Prostasome‐derived proteins capable of eliciting an immune response in prostate cancer patients. Int J Cancer 2006; 119: 847–53
   PubMed Web of Science ®Google Scholar
• Murphy B. F., Kirszbaum L., Walker I. D., dÁpice A. J. F. SP‐40,40, a newly identified normal human serum protein found in the SC5b‐9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest 1988; 81: 1858–64
   PubMed Web of Science ®Google Scholar
• Schröder F. H., Hermanek P., Denis L., Fair W. R., Gospodarowicz M. K., Pavone‐Macaluso M. The TNM classification of prostate cancer. Prostate 1992; 4: 129–38
   Google Scholar
• Rosenberg M. E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633–45
   PubMed Web of Science ®Google Scholar
• Jenne D. E., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem Sci 1992; 17: 154–9
   PubMed Web of Science ®Google Scholar
• Collard M. W., Griswold M. D. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry 1987; 26: 3297–303
   PubMed Web of Science ®Google Scholar
• Leger J. G., Montpetit M. L., Tenniswood M. P. Characterization and cloning of androgen–repressed mRNAs from rat ventral prostate. Biochem Biophys Res Commun 1987; 147: 196–203
   PubMed Web of Science ®Google Scholar
• Kadomatsu K., Anzano M. A., Slayter M. V., Winokur T. S., Smith J. M., Sporn M. B. Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N‐nitroso‐N‐methylurea in rat prostate and seminal vesicle. Cancer Res 1993; 53: 1480–3
   PubMedGoogle Scholar
• Steinberg J., Oyasu R., Lang S., Sintich S., Rademaker A., Lee C., et al. Intracellular levels of SGP‐2 (Clusterin) correlate with tumour grade in prostate cancer. Clin Cancer Res 1997; 3: 1707–11
   PubMed Web of Science ®Google Scholar
• Morrissey C., Lakins J., Moquin A., Hussain M., Tenniswood M. An antigen capture assay for the measurement of serum clusterin concentrations. J Biochem Biophys Methods 2001; 48: 13–21
   PubMedGoogle Scholar
• Burkey B. F., deSilva H. V., Harmony J. A. Intracellular processing of apolipoprotein J precursor to the mature heterodimer. J Lipid Res 1991; 32: 1039–48
   PubMedGoogle Scholar
• Kirszbaum L., Sharpe J. A., Murphy B., d'Apice A. J., Classon B., Hudson P., et al. Molecular cloning and characterization of the novel, human complement‐associated protein, SP‐40,40: a link between the complement and reproductive systems. EMBO J 1989; 8: 711–18
   PubMed Web of Science ®Google Scholar
• Kounnas M. Z., Loukinova E. B., Stefansson S., Harmony J. A., Brewer B. H., Strickland D. K., et al. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 1995; 270: 232–4
   Google Scholar
• Ghiso J., Matsubara E., Koudinov A., Choi‐Miura N. H., Tomita M., Wisniewski T., et al. The cerebrospinal‐fluid soluble form of Alzheimer's amyloid beta is complexed to SP‐40,40 (apolipoprotein J), an inhibitor of the complement membrane‐attack complex. Biochem J 1993; 293: 27–30
   PubMed Web of Science ®Google Scholar
• de Silva H. V., Harmony J. A., Stuart W. D., Gil C. M., Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990; 29: 5380–9
   PubMed Web of Science ®Google Scholar
• Tsuruta J. K., Wong K., Fritz I. B., Griswold M. D. Structural analysis of sulphated glycoprotein 2 from amino acid sequence. Relationship to clusterin and serum protein 40,40. Biochem J 1990; 268: 571–8
   PubMed Web of Science ®Google Scholar
• Jenne D. E., Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989; 86: 7123–7
   PubMed Web of Science ®Google Scholar
• Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., Chinnaiyan A. M., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224–35
   PubMed Web of Science ®Google Scholar